Summary
Background Guselkumab, an anti-interleukin-23 monoclonal antibody, has demonstrated significant efficacy in phase III psoriasis trials. Objectives To evaluate the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis who had an inadequate response to ustekinumab. Methods In this phase III, randomized, double-blind study, 871 patients received open-label ustekinumab (45 mg or 90 mg) at weeks 0 and 4. At week 16, 268 patients with an inadequate response to ustekinumab [Investigator's Global Assessment (IGA) ≥ 2] were randomized (double-blind) to guselkumab 100 mg or to continue ustekinumab; 585 of 871 patients (67%) with IGA 0/1 at week 16 continued open-label ustekinumab. The primary end point was the number of visits at which randomized patients achieved IGA 0/1 and at least a two-grade improvement (from week 16) from week 28 to week 40. Improvement ≥ 90% or 100% in Psoriasis Area and Severity Index (PASI 90/100) and Dermatology Life Quality Index (DLQI) of 0/1 were also assessed. Results The mean number of visits at which patients achieved IGA 0/1 and at least a two-grade improvemen (week 28-40) was significantly greater in the guselkumab group vs. the randomized ustekinumab group (1Á5 vs. 0Á7; P < 0Á001); greater proportions of patients in the guselkumab group achieved IGA 0/1 and at least a two-grade improvement at week 28 (31Á1% vs. 14Á3%; P = 0Á001) and week 52 (36Á3% vs. 17Á3%; P < 0Á001). Greater proportions of patients treated with guselkumab achieved PASI 90, PASI 100 and DLQI 0/1 at week 52. After week 16, 64Á4% of patients in the guselkumab group and 55Á6% in the ustekinumab group had at least one adverse event (AE); infections were the most frequent AE type. Overall, 6Á7% (n = 9) of patients in the guselkumab group had at least one serious AE compared with 4Á5% (n = 6) for the ustekinumab group. Conclusions Patients treated with ustekinumab who did not achieve an IGA of 0/1 by week 16 derived significant benefit from switching to guselkumab.
What's already known about this topic?
• Interleukin (IL)-23/IL-17 is the major pathway that drives the chronic inflammation underlying the pathophysiology of psoriasis.
• Ustekinumab is a monoclonal antibody targeting IL-12 and IL-23 and is currently approved for patients with plaque psoriasis. • Guselkumab is a novel anti-IL-23 monoclonal antibody and has demonstrated high efficacy in patients with plaque psoriasis in two recent phase III trials.
What does this study add?
• Guselkumab demonstrated greater efficacy compared with ustekinumab among patients who failed to achieve an Investigator's Global Assessment score of 0 or 1 with ustekinumab therapy.
• The types of adverse events (AEs) with guselkumab and ustekinumab were similar, with infections being the most common.
• A slightly higher incidence of AEs was reported in the guselkumab group, primarily driven by AEs of back pain, psoriatic arthropathy and mild injection site reactions.
Psoriasis is a chronic immune-mediated skin disease, with a prevalence between 1Á5% and 5% in many developed countries. 1 Patients were ineligible if they had severe, progressive or uncontrolled medical conditions or had a malignancy or history of malignancy within 5 years (with the exception of nonmelanoma skin cancer). Patients were excluded if they had a history or symptoms of active tuberculosis (TB) or if they tested positive for hepatitis B or seropositive for antibodies to hepatitis C. Patients could not have received prior treatment with guselkumab or ustekinumab, therapeutic agents targeted to IL-12, IL-17 or IL-23 within 6 months of first administration of the study agent, anti-TNF therapy within 3 months or five half-lives of first study agent administration, or any systemic immunosuppressants or phototherapy within 4 weeks of first administration of the study agent.
Trial design
NAVIGATE was a phase III, randomized, double-blind trial conducted between October 2014 and May 2016 at 100 sites in 10 countries. The study included a 16-week open-label period, a 28-week randomized active-treatment period, and a 16-week follow-up period (Fig. 1) . All patients received openlabel ustekinumab (45 mg for patients weighing ≤ 100 kg; 90 mg for patients weighing > 100 kg) at weeks 0 and 4. At week 16, patients with an IGA ≥ 2 (i.e. inadequate response to ustekinumab) were randomized to guselkumab 100 mg at weeks 16, 20 and every 8 weeks thereafter, or to continue ustekinumab at week 16 and every 12 weeks thereafter. Randomization was performed using an interactive web response system with patients stratified by baseline weight (≤ 100 kg vs. > 100 kg) and study site. Placebo injections were administered to maintain blinding. Patients with an IGA of 0 or 1 continued receiving open-label ustekinumab at week 16 and every 12 weeks. Ustekinumab and guselkumab injections were administered through week 40 and week 44, respectively. Patients were followed up for efficacy through week 52 and safety through week 60.
This study was conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice. The protocol was approved by the investigational review board/ ethics committee at each site. All patients gave written informed consent before any study-related procedures were performed. The trial was registered with EudraCT (2014-000721-20) and clinicaltrials.gov (NCT02203032).
Trial assessments
Clinical efficacy was evaluated using the IGA [cleared (0), minimal (1), mild (2), moderate (3) or severe (4)] 17 and PASI (scale of 0-72; higher scores indicating more severe disease). The primary end point was the number of visits at which patients achieved an IGA score of 0 or 1 and at least a two-grade improvement relative to week 16 from week 28 through week 40, with a maximum of four visits, for randomized patients [i.e. those with an inadequate response (IGA ≥ 2) to ustekinumab at week 16]. Major secondary end points for randomized patients were the number of visits at which patients achieved an IGA score of 0 from week 28 through week 40, the number of visits at which patients achieved ≥ 90% improvement in PASI score 16 (PASI 90) from week 28 through week 40, and the proportion of patients achieving an IGA of 0 or 1 and at least a two-grade improvement relative to week 16 at week 28. Patient-reported outcome assessments included the Dermatology Life Quality Index (DLQI), 18 a dermatology-specific instrument (scale 0-30) to assess overall quality of life with higher scores indicating a greater effect of disease on quality of life, and the Psoriasis Symptoms and Signs Diary (PSSD), 19 a self-administered questionnaire (0-100) measuring the severity of psoriasis symptoms (itch, pain, stinging, burning and skin tightness) and signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) over the previous 7 days, with higher scores indicating greater disease severity. Patients were monitored for adverse events (AEs), vital signs and clinical laboratory (chemistry and haematology) values, through week 60. Serum samples were collected through week 60, and a highly sensitive, drug-tolerant electrochemiluminescence immunoassay was used to assess the presence of antibodies to guselkumab and antibodies to ustekinumab in patients who received at least one administration of guselkumab or ustekinumab, respectively.
Statistical analyses
The primary and major secondary analyses were performed for patients randomized at week 16. Data were analysed by randomized treatment group. Patients who discontinued study treatment owing to a lack of efficacy or an AE of worsening of psoriasis were considered nonresponders from that point onward, as were patients who started a protocol-prohibited medication/therapy that could improve psoriasis. Missing data for randomized patients were imputed as nonresponse for categorical variables. The primary and major secondary end points in the randomized treatment groups were compared using the Cochran-Mantel-Haenszel (CMH) row mean score test for ordinal endpoints and the CMH Chi-Square test for binary endpoints, both stratified by baseline weight (≤ 100 kg, > 100 kg). The sample size (130 patients per treatment group) was chosen to have approximately 98% power to detect a treatment difference between ustekinumab and guselkumab for the primary end point at a significance level of 0Á05 (two-sided). Safety analyses included all patients who received at least one administration of study agent, and AEs were summarized according to the actual treatment received.
Results

Trial population
A total of 872 patients were enrolled, and 871 received openlabel ustekinumab. Baseline demographics and disease characteristics were generally similar in the randomized treatment groups and the nonrandomized treatment group, with the exception that a higher proportion of patients in the randomized groups received previous anti-TNF therapy (Table 1) .
A total of 18 patients discontinued ustekinumab through week 16 ( Fig. 2) . At week 16, 268 patients had an IGA score ≥ 2 and were randomized in a double-blinded fashion to guselkumab 100 mg (n = 135) or ustekinumab (n = 133); 585 patients had an IGA score of 0 or 1 and continued openlabel ustekinumab (nonrandomized group). Among the randomized patients, 29 [guselkumab, n = 9 (6Á7%); ustekinumab, n = 20 (15Á0%)] discontinued the study agent from week 16 to week 44. Overall, 17 patients (2Á9%) who continued open-label ustekinumab discontinued treatment from week 16 to week 40.
Clinical efficacy
During the open-label run-in, 68Á5% of patients (589 of 860) achieved an IGA score of 0 or 1, 73Á7% achieved PASI 75 and 49% achieved PASI 90 at week 16.
Among randomized patients, the guselkumab group had a significantly higher mean number of visits at which patients had an IGA score of 0 or 1 and at least a two-grade improvement relative to week 16 from week 28 through week 40 (primary end point) compared with the ustekinumab group (1Á5 vs. 0Á7; P < 0Á001) ( Table 2 ). All major secondary end points were also met. The mean number of visits at which patients had a PASI 90 relative to baseline, between week 28 and week 40, was significantly higher in the guselkumab group than in the randomized ustekinumab group (2Á2 vs. 1Á1; P < 0Á001). The mean number of visits at which patients had an IGA score of 0 between week 28 and week 40 was significantly greater for patients in the guselkumab group compared with the randomized ustekinumab group (0Á9 vs. 0Á4; P < 0Á001). The proportion of patients with an IGA score of 0 or 1 and at least a two-grade improvement relative to week 16 at week 28 was significantly greater in the guselkumab group than in the randomized ustekinumab group (31Á1% vs. 14Á3%; P = 0Á001) ( Table 2) . Additionally, at week 52, 36Á3% of patients in the guselkumab group achieved this response vs. 17Á3% in the randomized ustekinumab group (P < 0Á001).
Among randomized patients, the mean PASI scores at week 16 were 9Á8 in the guselkumab group and 10Á6 in the ustekinumab group; at week 52, the mean decrease in PASI score from week 16 was numerically greater in the guselkumab group compared with ustekinumab (6Á7 vs. 2Á5). The proportions of patients with an IGA score of 0 or 1 and at least a two-grade improvement relative to week 16 and the proportions of patients achieving PASI 75/90/100 responses relative to baseline were consistently numerically greater in the guselkumab group than in the randomized ustekinumab group from week 20 through week 52 (Fig. 3) . Response rates increased in the guselkumab group from week 16, reaching a maximum at week 36 (20 weeks postrandomization). Response rates in the randomized ustekinumab group slightly increased from week 16, reaching a plateau at week 32 with a periodic loss of response every 12 weeks, which corresponds to the trough time point of the every-12-week ustekinumab injections. IGA and PASI responses in both groups were generally maintained through week 52 (Fig. 3) , with separation between the groups occurring as early as week 20 (4 weeks postrandomization) and increasing over time. At week 52, greater proportions of patients treated with guselkumab achieved PASI 90 (51Á1% vs. 24Á1%; P < 0Á001) and PASI 100 (20Á0% vs. 7Á5%; P = 0Á003) compared with the randomized ustekinumab group.
A total of 585 patients who had an IGA score of 0 or 1 at week 16 continued open-label ustekinumab. At week 52, 81Á1% of these patients maintained this response, with 42Á6% having an IGA score of 0. Nearly all patients (95Á7%) in the nonrandomized ustekinumab group had a PASI 75 at week 16, 69Á7% had a PASI 90 and 27Á2% had a PASI 100. These levels of response were maintained through week 52.
Patient-reported outcome assessments
At week 16, 103 patients in the guselkumab group and 105 patients in the randomized ustekinumab group had a DLQI score > 1 ( Table 2) . Of these patients, a significantly greater proportion of patients in the guselkumab group had a DLQI score of 0 or 1 at week 52 compared with the ustekinumab group (38Á8% vs. 19Á0%; P = 0Á002). The mean DLQI scores at week 16 for all randomized patients were 7Á5 and 6Á8 in the guselkumab and ustekinumab groups, respectively. At week 52, the mean changes in DLQI from week 16 were À3Á8 in the guselkumab group and 0Á3 in the ustekinumab group. Among randomized patients who had a PSSD sign score > 0 or a PSSD symptom score > 0 at week 16, significantly greater proportions of patients treated with guselkumab had a PSSD sign score of 0 or a symptom score of 0 at week 52 compared with the ustekinumab group ( Table 2) . Table 3 ). The most common AEs were nasopharyngitis (5Á4%) and upper respiratory infection (3Á8%). Eleven patients (1Á3%) had at least one serious AE (SAE). Two patients reported a serious infection (pneumonia and anal abscess). Malignancies occurred in two patients (basal cell carcinoma in both). No opportunistic infections or cases of active TB, major adverse cardiovascular events or deaths occurred through week 16.
Adverse events in the randomized guselkumab and ustekinumab groups (weeks 16-60)
In the two randomized groups, 64Á4% of patients in the guselkumab group and 55Á6% of patients in the ustekinumab group had at least one AE from week 16 through week 60 (Table 3) . Infections were the most common AEs in both randomized groups (guselkumab 41Á5%; ustekinumab 35Á3%). The higher overall rate of AEs in the guselkumab group appeared to be related to a higher incidence of AEs reported in musculoskeletal and connective tissue disorders (guselkumab 12Á6%; ustekinumab 6Á8%), with higher proportions of AEs reported for back pain and psoriatic arthropathy, and general disorders and administration site conditions (guselkumab 11Á9%; ustekinumab 1Á5%), with the majority being injection site reactions (all mild). However, no consistent patterns were observed among these AEs. In the randomized groups, SAEs were reported in nine patients treated with guselkumab (6Á7%) and six patients treated with ustekinumab (4Á5%) ( Table 3) . One serious infection occurred (bacterial arthritis in the guselkumab group). No opportunistic infections or cases of active TB were reported. Two malignancies were reported [transitional cell carcinoma of the bladder and a fatal squamous cell carcinoma of the neck (of origin unknown) in the guselkumab group]. Three patients had a myocardial infarction (one female patient aged 69 years and one male patient aged 52 years in the guselkumab group and one male patient in the ustekinumab group aged 66 years); all three patients had at least two known cardiovascular risk factors. The patient with squamous cell carcinoma of the neck discussed previously (a 66-year-old man) was diagnosed just prior to the final (week 60) study visit and died approximately 9 months later. Injection site reactions were uncommon between week 16 and week 60; all were 17 patients discontinued study agent 7 due to AEs 1 due to lack of efficacy 5 withdrew from the study 1 lost to follow-up 3 other 9 patients discontinued study agent 3 due to AEs 3 due to lack of efficacy 2 withdrew from the study 1 noncompliance with study drug 20 patients discontinued study agent 2 due to AEs 10 due to lack of efficacy 5 withdrew from the study 1 lost to follow-up 2 other 18 patients discontinued study agent 2 due to AEs 1 due to lack of efficacy 6 withdrew from the study 3 lost to follow-up 4 protocol violations 2 other mild. There were no anaphylactic or serum sickness-like reactions or AEs of Crohn disease.
Adverse events in the nonrandomized open-label ustekinumab continuation group (weeks 16-60)
The most common AEs in the nonrandomized ustekinumab group were nasopharyngitis and upper respiratory tract infections (Table 3) .
Twenty patients (3Á4%) had at least one SAE from week 16 to week 60. Five patients had a serious infection after week 16 (appendicitis, epididymitis, periodontitis, paraspinal abscess -each occurred in one patient; salpingitis and urinary tract infection, both of which occurred in the same patient); there were no opportunistic infections or cases of active TB. The following four malignancies occurred: bile duct cancer, fatal metastatic pancreatic carcinoma, basal cell carcinoma and squamous cell carcinoma of the skin. One patient had a myocardial infarction; this patient had a history of multiple known risk factors. One death occurred (the previously mentioned patient with metastatic pancreatic carcinoma). Two injection site reactions occurred [two of 1734 injections (0Á1%)], and none were severe. There were no anaphylactic or serum sickness-like reactions or AEs of Crohn disease.
Immunogenicity
Through week 60, 9Á0% of patients (12 of 134) treated with guselkumab and 14Á7% of patients (125 of 853) treated with ustekinumab tested positive for antibodies to guselkumab or antibodies to ustekinumab, respectively.
Discussion
This controlled phase III study validates that guselkumab is effective in treating moderate-to-severe psoriasis in patients who did not achieve optimum clinical efficacy with ustekinumab. While ustekinumab is very effective in treating moderate-to-severe psoriasis, 6, 7 as with any therapeutic agent, not all patients reach the maximum response. Recent studies established that guselkumab, a monoclonal antibody that selectively targets IL-23, had substantial efficacy in adults with moderateto-severe psoriasis 8, 12, 15 and may be more effective than ustekinumab. Our results demonstrated that when patients who had an inadequate response to ustekinumab were randomized to guselkumab vs. continuing ustekinumab, guselkumab was superior across all end points measured, including the mean number of visits between week 28 and week 40 at which patients had an IGA of 0 or 1 and at least a two-grade improvement relative to week 16, an IGA score of 0 (cleared), and a PASI 90 response. Over time, guselkumab was also superior in the proportions of patients achieving clinical efficacy and patient-reported outcome end points through week 52. These results are significant considering that this population had an inadequate response to ustekinumab, and our findings provide dermatologists with an approach to switching from ustekinumab to guselkumab. This study employed an enrichment design of open-label treatment followed by randomization, which is a wellaccepted method, 20 specifically to evaluate treatment response in patients who had an inadequate response to ustekinumab. The randomization of patients either to the group continuing ustekinumab treatment or to the group initiating guselkumab treatment was necessary, as inadequate responders to ustekinumab also continued to improve after week 16. The ustekinumab dosage regimen evaluated in NAVIGATE was consistent with the approved dosing regimen in most regions worldwide; thus, dose escalation was not permitted. The study utilized a relatively high level of efficacy to define ustekinumab responders (IGA 0/1, cleared or minimal), consistent with patients' desires for greater efficacy. Two types of end points were employed, i.e. the number of visits at which patients obtained a high degree of response and the proportion of patients achieving high levels of PASI and IGA response over time. The former assessed consistency of response at visits across a prespecified period of time after switching treatment and helps to address the differing peak and trough concentrations of the two biologics resulting from their respective administration regimens; the latter end points, proportions of patients with IGA and PASI responses at specific visits, are more intuitive and easily interpreted. Regardless of the end points used, the number of visits at which response was achieved or the proportion of patients who achieved response over time, the outcomes consistently showed greater efficacy with guselkumab. In the randomized groups, PASI 75/90/100 response rates were greater in the guselkumab group, with separation between the groups observed at week 20 (4 weeks after the first guselkumab administration); response rates peaked between week 32 and week 36 and were generally maintained through week 52. Responses were high, considering a patient population with an inadequate response to an effective drug such as The safety profiles of guselkumab and ustekinumab were generally consistent with previous studies. In the pivotal phase III studies, there were comparable rates of AEs and SAEs among guselkumab, placebo and adalimumab and between ustekinumab and placebo. 8, 12, 15, 21 Notably, in this study, during the randomized controlled period, the incidence of AEs was slightly higher in the guselkumab group compared with the randomized ustekinumab group, which was primarily due to higher rates of AEs reported in musculoskeletal and connective tissue disorders (e.g. back pain and psoriatic arthropathy) and general disorders and administration site conditions (e.g. injection site reactions, with all injection site reactions being mild). In both randomized groups, infections were the most common type of AE, and the incidence of infections was similar between the two groups. One serious infection occurred in the guselkumab group; no hypersensitivity reactions or AEs of Crohn disease occurred in these groups. Few patients treated with guselkumab had an injection site reaction, and all reactions were considered mild. There were no signals with regard to SAEs or hypersensitivity reactions when transitioning from ustekinumab to guselkumab, despite employing a guselkumab loading dose. The incidence of antibodies to guselkumab was in line with those reported in the larger phase III VOYAGE 1 (5Á3%) 8 and VOYAGE 2 (6Á6%) 12 trials.
While an explanation for the superior efficacy of guselkumab compared with ustekinumab observed in this study is not Our study provides valuable information to clinicians regarding transitioning from ustekinumab to guselkumab and the subsequent efficacy and safety of switching without a washout in a population of inadequate responders. Despite the rigorous design of the study, there are several limitations. The primary end point of this trial does not intuitively translate into clinical response; however, it is supplemented by response rates using IGA and PASI (standard assessments in dermatology trials). In addition, the primary end point covered a limited time period from week 28 to week 40. In this trial, week 16 was selected to evaluate the adequacy of response to ustekinumab treatment. A decision to administer a third dose of ustekinumab is made at week 16, and this is therefore a practical time point to consider a switch to a potentially more effective treatment. While some patients may not have reached maximum response to ustekinumab based on the kinetics of response curves in this trial and others, 6, 7 the incremental improvement beyond week 16 with continued ustekinumab treatment was modest and lower than the efficacy increase observed for guselkumab in this patient population at all assessment time points beyond week 16.
In conclusion, we demonstrated in a controlled enrichment design study that switching to guselkumab is an effective strategy in patients who fail to achieve a high level of response with ustekinumab, and the transition was not associated with additional safety concerns. These results will be useful to dermatologists managing psoriasis as new medications emerge, particularly considering high patient treatment goals and the relationship of skin clearance to improved quality of life. 22, 23 
